Skip to main content

Advertisement

SpringerLink
Log in

Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010–2020

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Primary breast salivary gland-type carcinoma has weak evidence to support its management due to its rare occurrence and limited data regarding its clinicopathological features and prognosis. Therefore, this study aimed to assess clinicopathological features and prognosis for this type of carcinoma diagnosed over the past decade and compared those to the common breast invasive carcinoma of no special type (NST).

Methods

This study used the Surveillance, Epidemiology, and End Results (SEER) database to extract data regarding primary breast salivary gland-type carcinoma. Using a propensity score-matching approach, the prognosis was compared with invasive carcinoma, NST.

Results

This study included 488 cases of salivary gland-type carcinoma and 375,660 cases of invasive carcinoma, NST, giving an occurrence ratio of 1 to 770. Adenoid cystic carcinoma (81%) formed the majority of salivary gland-type carcinoma, followed by secretory carcinoma (13%). For salivary gland-type carcinoma, acinic cell carcinoma histological type, tumor grade 3, HER2-overexpressed status, and higher AJCC stage groups were significant worse prognostic factors for breast cancer-specific survival in univariate analyses (p < 0.05). Nonetheless, tumor grade 3 and higher AJCC stage groups remained as significant independent prognostic factors in multivariate analysis (p < 0.05). The apparent better breast cancer-specific survival of salivary gland-type carcinoma as compared to that of invasive carcinoma, NST, was diminished following adjustment for differences in baseline clinicopathological features and treatment-related variables.

Conclusions

This study suggests that when managing primary breast salivary gland-type carcinoma, greater emphasis should be given to the tumor grade and AJCC stage group in addition to acinic cell carcinoma histological type and HER2 overexpression. Conventional prognostic factors are important as salivary gland-type carcinoma had similar prognosis as invasive carcinoma, NST, following adjustment for confounding variables.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

Data used in this study are accessible to public from Surveillance, Epidemiology, and End Results Program (https://seer.cancer.gov/data/access.html).

References

  1. Foschini MP, Scarpellini F, Gown AM, Eusebi V. Differential expression of myoepithelial markers in salivary, sweat and mammary glands. Int J Surg Pathol. 2000;8:29–37.

    Article  PubMed  Google Scholar 

  2. Emerick C, Mariano FV, Vargas PA, Nör JE, Squarize CH, Castilho RM. Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: different clinical outcomes to the same tumor. Crit Rev Oncol Hematol. 2022;179: 103792.

    Article  PubMed  Google Scholar 

  3. WHO Classification of Tumours Editorial Board, editor. Breast tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019. Available from: https://publications.iarc.fr/581.

  4. Lakhani SR, Ellis IO, Schnitt S, Tan PH, van de Vijver M, editors. WHO Classification of Tumours of the Breast. 4th edn. International Agency for Research on Cancer; 2012.

  5. Eble JN, Tavassoli FA, Devilee P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 3rd edn. International Agency for Research on Cancer; 2003.

  6. National Comprehensive Cancer Network. Breast Cancer (Version 4.2023). 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  7. Foley NM, Coll JM, Lowery AJ, Hynes SO, Kerin MJ, Sheehan M, et al. Re-appraisal of estrogen receptor negative/progesterone receptor positive (ER−/PR+) breast cancer phenotype: true subtype or technical artefact? Pathol Oncol Res. 2018;24:881–4.

    Article  CAS  PubMed  Google Scholar 

  8. Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

    Article  Google Scholar 

  9. Hoda SA, Rosen PP, Brogi E, Koerner FC. Rosen’s breast pathology. USA: Lippincott Williams & Wilkins; 2020.

    Google Scholar 

  10. Slodkowska E, Xu B, Kos Z, Bane A, Barnard M, Zubovits J, et al. Predictors of outcome in mammary adenoid cystic carcinoma: a multi-institutional study. Am J Surg Pathol. 2020;44:214–23.

    Article  PubMed  Google Scholar 

  11. Khoury T, Rosa M, Nayak A, Karabakhtsian R, Fadare O, Li Z, et al. Clinicopathologic predictors of clinical outcomes in mammary adenoid cystic carcinoma: a multi-institutional study. Mod Pathol. 2023;36: 100006.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen M, Pu T, Wei B, Bu H, Tang P, Zhang Z. Genomic landscape of secretory carcinoma of the breast with axillary lymph node metastasis. Pathol Res Pract. 2022;231: 153790.

    Article  CAS  PubMed  Google Scholar 

  13. Li L, Wu N, Li F, Li L, Wei L, Liu J. Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma. Cancer Biol Med. 2019;16:139–46.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, et al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology. 2019;75:213–24.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016;113:721–5.

    Article  CAS  PubMed  Google Scholar 

  16. Ajkunic A, Skenderi F, Shaker N, Akhtar S, Lamovec J, Gatalica Z, et al. Acinic cell carcinoma of the breast: a comprehensive review. Breast. 2022;66:208–16.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sørensen M. HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis. Front Oncol Switzerland. 2021;11: 693394.

    Article  CAS  Google Scholar 

  18. Trihia HJ, Valavanis C, Novkovic N, Koutsodontis G, Petraki M, Efstathiou E. Polymorphous adenocarcinoma of the breast-an exceptionally rare entity: clinicopathological description of a case and brief review. Breast J. 2020;26:261–4.

    Article  PubMed  Google Scholar 

  19. Asioli S, Marucci G, Ficarra G, Stephens M, Foschini MP, Ellis IO, et al. Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch. 2006;448:29–34.

    Article  PubMed  Google Scholar 

  20. Galdirs TM, Kappler M, Reich W, Eckert AW. Current aspects of salivary gland tumors—a systematic review of the literature. GMS Interdiscip Plast Reconstr Surg DGPW. 2019;8.

  21. Johns N, Dixon JM. Should patients with early breast cancer still be offered the choice of breast conserving surgery or mastectomy? Eur J Surg Oncol. 2016;42:1636–41.

    Article  CAS  PubMed  Google Scholar 

  22. Mueller SK, Haderlein M, Lettmaier S, Agaimy A, Haller F, Hecht M, et al. Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer. J Clin Med. 2022;11:720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Miyai K, Schwartz MR, Divatia MK, Anton RC, Park YW, Ayala AG, et al. Adenoid cystic carcinoma of breast: recent advances. World J Clin cases. 2014;2:732–41.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Treitl D, Radkani P, Rizer M, El Hussein S, Paramo JC, Mesko TW. Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature. Breast Cancer. 2018;25:28–33.

    Article  PubMed  Google Scholar 

  25. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw. 2011;42:1–52.

    Article  Google Scholar 

Download references

Acknowledgements

The author was supported by the Universiti Sains Malaysia Research University Grant for Individual (RUI, Grant No: 1001/CIPPT/8012230) and Bridging Grant (Grant No: 304.CIPPT.6316263). The author appreciates the comments provided by Dr. Suet Kee Loo in preparation of this manuscript.

Author information

Authors and Affiliations

  1. Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia

    Ewe Seng Ch’ng

  2. Cancer Research Malaysia, Selangor, Malaysia

    Ewe Seng Ch’ng

Authors
  1. Ewe Seng Ch’ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The work reported in the paper has been solely performed by the author.

Corresponding author

Correspondence to Ewe Seng Ch’ng.

Ethics declarations

Conflict of interests

The author declares no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ch’ng, E.S. Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010–2020. Breast Cancer 31, 496–506 (2024). https://doi.org/10.1007/s12282-024-01564-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-024-01564-8

Keywords

Search

Navigation